Skip to content

Study · Randomized controlled trial · n = 124 · 2019

9 results

Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.

Wijkman MO, Dena M, Dahlqvist S, Sofizadeh S, Hirsch I, Tuomilehto J, Mårtensson J, Torffvit O, Imberg H, Saeed A, Lind M

Journal of clinical hypertension (Greenwich, Conn.)5 Dec 2018Cited by 14 (Europe PMC)

PMID30515978 (opens in a new tab)PMCIDPMC8030426 (opens in a new tab)DOI10.1111/jch.13447 (opens in a new tab)PepBankPUB-30515978
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes, the regression coefficient for baseline diastolic blood pressure differed significantly between the liraglutide and placebo groups.

    In plain wordsIn people with type 2 diabetes on insulin, starting diastolic blood pressure predicted blood pressure change differently with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    Not applicableDiastolic blood pressure as predictor, liraglutide versus placebo
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The regression coefficients differed significantly between the liraglutide group and the placebo group only for diastolic blood pressure (P = 0.037) and mean CGM (P = 0.021).
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  2. 02HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes, the regression coefficient for baseline mean continuous glucose monitoring glucose differed significantly between the liraglutide and placebo groups.

    In plain wordsIn people with type 2 diabetes on insulin, starting average glucose predicted blood pressure change differently with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    Not applicableMean CGM glucose as predictor, liraglutide versus placebo
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The regression coefficients differed significantly between the liraglutide group and the placebo group only for diastolic blood pressure (P = 0.037) and mean CGM (P = 0.021).
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  3. 03HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes given liraglutide, higher baseline systolic blood pressure predicted a greater reduction in systolic blood pressure.

    In plain wordsIn people with type 2 diabetes on insulin and liraglutide, higher starting blood pressure predicted a larger blood pressure drop.

    Peptide
    Liraglutide
    Outcome
    Not applicableBaseline systolic blood pressure as predictor of SBP reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A greater reduction in SBP among liraglutide-treated patients was predicted by higher baseline values of SBP (P < 0.0001) and diastolic blood pressure (P = 0.012), and by lower baseline values of mean glucose measured by continuous glucose monitoring (CGM; P = 0.044), and serum fasting C-peptide (P = 0.015).
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  4. 04HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes given liraglutide, higher baseline diastolic blood pressure predicted a greater reduction in systolic blood pressure.

    In plain wordsIn people with type 2 diabetes on insulin and liraglutide, higher starting diastolic blood pressure predicted a larger drop in systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    Not applicableBaseline diastolic blood pressure as predictor of SBP reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A greater reduction in SBP among liraglutide-treated patients was predicted by higher baseline values of SBP (P < 0.0001) and diastolic blood pressure (P = 0.012), and by lower baseline values of mean glucose measured by continuous glucose monitoring (CGM; P = 0.044), and serum fasting C-peptide (P = 0.015).
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  5. 05HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes given liraglutide, lower baseline mean glucose on continuous glucose monitoring predicted a greater reduction in systolic blood pressure.

    In plain wordsIn people with type 2 diabetes on insulin and liraglutide, lower starting average glucose predicted a larger blood pressure drop.

    Peptide
    Liraglutide
    Outcome
    Not applicableBaseline mean CGM glucose as predictor of SBP reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A greater reduction in SBP among liraglutide-treated patients was predicted by higher baseline values of SBP (P < 0.0001) and diastolic blood pressure (P = 0.012), and by lower baseline values of mean glucose measured by continuous glucose monitoring (CGM; P = 0.044), and serum fasting C-peptide (P = 0.015).
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  6. 06HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes given liraglutide, lower baseline serum fasting C-peptide predicted a greater reduction in systolic blood pressure.

    In plain wordsIn people with type 2 diabetes on insulin and liraglutide, lower starting C-peptide predicted a larger blood pressure drop.

    Peptide
    Liraglutide
    Outcome
    Not applicableBaseline fasting C-peptide as predictor of SBP reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A greater reduction in SBP among liraglutide-treated patients was predicted by higher baseline values of SBP (P < 0.0001) and diastolic blood pressure (P = 0.012), and by lower baseline values of mean glucose measured by continuous glucose monitoring (CGM; P = 0.044), and serum fasting C-peptide (P = 0.015).
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  7. 07HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes, systolic blood pressure reduction during the trial correlated directly with change in body weight.

    In plain wordsIn people with type 2 diabetes on insulin, a bigger blood pressure drop went along with a bigger change in body weight.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of SBP reduction with change in body weight
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During the trial period, SBP reduction correlated directly with change in body weight and BMI, but not with change in HbA1c.
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  8. 08HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes, systolic blood pressure reduction during the trial correlated directly with change in BMI.

    In plain wordsIn people with type 2 diabetes on insulin, a bigger blood pressure drop went along with a bigger change in BMI.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of SBP reduction with change in BMI
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During the trial period, SBP reduction correlated directly with change in body weight and BMI, but not with change in HbA1c.
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.
  9. 09HumanRandomized controlled trialOther

    In insulin-treated adults with type 2 diabetes, systolic blood pressure reduction during the trial did not correlate with change in HbA1c.

    In plain wordsIn people with type 2 diabetes on insulin, the blood pressure drop was not linked to the change in HbA1c.

    Peptide
    Liraglutide
    Outcome
    No significant changeCorrelation of SBP reduction with change in HbA1c
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During the trial period, SBP reduction correlated directly with change in body weight and BMI, but not with change in HbA1c.
    1 context sentence
    Summary · context
    We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.